Glycosylated specificity exchangers
The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
1. An isolated glycoconjugate peptide joined to a support, wherein said glycoconjugate peptide comprises an HIV gp120 binding fragment of CD4 synthetically conjugated to gal α (1,3) gal β.
2. The isolated glycoconjugate peptide of claim 1 , wherein said gal α (1,3) gal β is synthetically conjugated to said HIV gp120 binding fragment of a CD4 by attachment at one amino acid.
3. The isolated glycoconjugate peptide of claim 1 , wherein said HIV gp120 binding fragment of a CD4 is less than 200 amino acids in length.
4. The isolated glycoconjugate peptide of claim 1 , wherein said HIV gp120 binding fragment of a CD4 is less than 150 amino acids in length.
5. The isolated glycoconjugate peptide of claim 1 , wherein said HIV gp120 binding fragment of a CD4 is less than 100 amino acids in length.
6. The isolated glycoconjugate peptide of claim 1 , wherein said HIV gp120 binding fragment of a CD4 is less than 50 amino acids in length.
7. The isolated glycoconjugate peptide of claim 1 , wherein said HIV gp120 binding fragment of a CD4 is less than 25 amino acids in length.
8. The isolated glycoconjugate peptide of claim 1 , wherein said HIV gp120 binding fragment of a CD4 is less than or equal to 15 amino acids in length.
9. The isolated glycoconjugate peptide of claim 1 , wherein said gal α (1,3) gal β is synthetically conjugated to a hydroxylated amino acid.
10. The isolated glycoconjugate peptide of claim 1 , wherein said gal α (1,3) gal β is synthetically conjugated by an NH 2 -linkage.
11. The isolated glycoconjugate peptide of claim 1 , wherein said gal α (1,3) gal β is synthetically conjugated to the N-terminal end of said HIV gp120 binding fragment of a CD4.
12. The isolated glycoconjugate peptide of claim 2 , wherein said gal α (1,3) gal β is synthetically conjugated to a hydroxylated amino acid.
13. The isolated glycoconjugate peptide of claim 2 , wherein said gal α (1,3) gal β is synthetically conjugated by an N 2 -linkage.
14. The isolated glycoconjugate peptide of claim 2 , wherein said gal α (1,3) gal β is synthetically conjugated to the N-terminal end of HIV gp120 binding fragment of a CD4.
15. The isolated glycoconjugate peptide of claim 1 , wherein said support is plastic.
16. The isolated glycoconjugate peptide of claim 1 , wherein said support is a microtiter plate.